Stem Cell Therapy Market by Type (Allogeneic, Autologous), Therapeutic Application (Musculoskeletal, Wound & Injury, CVD, Surgery, and aGVHD), Cell Source (Adipose tissue, Bone Marrow, Neural, Embryo/Cord Blood derived, iPSCs) - Global Forecasts to 2021

幹細胞治療の世界市場予測(~2021年):同種幹細胞、自己幹細胞

◆タイトル:Stem Cell Therapy Market by Type (Allogeneic, Autologous), Therapeutic Application (Musculoskeletal, Wound & Injury, CVD, Surgery, and aGVHD), Cell Source (Adipose tissue, Bone Marrow, Neural, Embryo/Cord Blood derived, iPSCs) - Global Forecasts to 2021
◆商品コード:MAM-BT5049
◆調査・発行会社:MarketsandMarkets
◆発行日:2017年2月28日
◆ページ数:123
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名利用)USD5,650 ⇒換算¥638,450見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥751,450見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥920,950見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、幹細胞治療の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、種類別分析、用途別分析、ソース別分析、地域別分析、幹細胞治療の世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。

The global stem cell therapy market is estimated to grow at a CAGR of 11.0% during 2016 to 2021 to reach USD 145.8 million by 2021. Growth in the global stem cell therapy market is driven by factors such as the growing awareness of the therapeutic potency of stem cells in effective disease management, development of advanced genome-based cell analysis techniques, increasing public-private investments for development of stem cell therapies, identification of new stem cell lines, and developments in infrastructure related to stem cell banking and processing. In addition, countries such as Japan, South Korea, and China are offering new growth opportunities for players operating in this market. The North American region is expected to command the largest share in the stem cell therapy market in 2016.
Based on the type of therapy, the allogeneic stem cell therapy segment is estimated to command the larger share of the global stem cell therapy market in 2016. This growth can be attributed to the growing availability of allogeneic stem cell therapy products, wider therapeutic applications of allogeneic stem cells, easier production scale-up due to easy availability of sources of stem cells, and growing number of clinical trials of allogeneic stem cell therapies as compared to autologous stem cell therapies.

The stem cell therapy market is niche industry with a growing number of global and local companies involved in the development and commercialization of stem cell therapy products. Osiris Therapeutics, Inc. (U.S.), MEDIPOST Co., Ltd. (South Korea), Anterogen Co., Ltd. (South Korea), and Pharmicell Co., Ltd. (South Korea) were the leading players in the global stem cell therapy market in 2015. New product launches and approvals; expansions; and partnerships and agreements are the major strategies adopted by most of the market players to achieve growth in the stem cell therapy market during 2013–2016.

Research Coverage
This report studies stem cell therapy market based on type of therapy (allogeneic and autologous). These stem cell therapies are used for the treatment of various diseases (including musculoskeletal disorders, wound healing, CVDs, and GI diseases, among others). The report also studies, the factors (such as drivers, restraints, opportunities, and challenges) which affect the market growth in a positive and negative manner. It analyzes opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report forecasts the revenue of the market segments with respect to four main regions, namely, North America, Europe, Asia-Pacific, and the Rest of the World. The stem cell therapy market report strategically profiles the key players who are involved in the manufacturing and commercialization of stem cell therapy products and comprehensively analyze their market ranking and core competencies. The report tracks and analyzes competitive developments such as new product launches and enhancements; expansions; and partnerships and agreements in the stem cell therapy market.

Reasons to Buy the Report:
From an insight perspective, this research report focuses on various levels of analysis—market share analysis of the top players and company profiles, which together comprise and discuss basic views on the competitive landscape; emerging and high-growth segments of the stem cell therapy market; and high-growth regions and their respective drivers, restraints, challenges, and opportunities.

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help firms in garnering a greater market share. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

• Market Penetration: Comprehensive information on products offered by the top 10 players in the stem cell therapy market. The report analyzes the stem cell therapy market by type, therapeutic application, cell source, and region

• Product Development/Innovation: Detailed insights on research and development activities, developmental product pipeline, and new product launches in the stem cell therapy market

• Market Development: Comprehensive information about the lucrative emerging markets. The report analyzes the markets for various stem cell therapy products across four geographies (North America, Europe, Asia-Pacific, and the Rest of the World)

• Competitive Assessment: Assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the stem cell therapy market

【レポートの目次】

TABLE OF CONTENTS

1 INTRODUCTION 15
1.1 OBJECTIVES OF THE STUDY 15
1.2 MARKET DEFINITION 15
1.3 MARKET SCOPE 16
1.3.1 MARKETS COVERED 16
1.3.2 GEOGRAPHIC SCOPE 16
1.3.3 YEARS CONSIDERED FOR THE STUDY 17
1.4 CURRENCY 17
1.5 LIMITATIONS 17
1.6 STAKEHOLDERS 18

2 RESEARCH METHODOLOGY 19
2.1 RESEARCH DATA 19
2.1.1 SECONDARY DATA 20
2.1.1.1 Key data from secondary sources 20
2.1.2 PRIMARY DATA 21
2.1.2.1 Key data from primary sources 21
2.1.2.2 Breakdown of primaries 21
2.2 MARKET SIZE ESTIMATION 22
2.2.1 BOTTOM-UP APPROACH 22
2.2.2 TOP-DOWN APPROACH 23
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 24
2.4 RESEARCH ASSUMPTIONS 25

3 EXECUTIVE SUMMARY 26
3.1 INTRODUCTION 26
3.2 CONCLUSION 29

4 PREMIUM INSIGHTS 30
4.1 STEM CELL THERAPY MARKET OVERVIEW 30
4.2 REGIONAL ANALYSIS: STEM CELL THERAPY MARKET, BY TYPE,
2016 VS. 2021 (USD MILLION) 31
4.3 GLOBAL STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION,
2016–2021 (USD MILLION) 32
4.4 REGIONAL ANALYSIS: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2016 VS. 2021 (USD MILLION) 33

5 MARKET OVERVIEW 34
5.1 INTRODUCTION 35
5.2 MARKET DYNAMICS 35
5.2.1 MARKET GROWTH DRIVERS 36
5.2.1.1 Growing awareness related to the therapeutic potency of stem cells in effective disease management 36
5.2.1.2 Development of advanced genome-based cell analysis techniques 37
5.2.1.3 Increasing public-private investments for the development of stem cell therapies 37
5.2.1.4 Development in infrastructure related to stem cell banking and processing 38
5.2.2 MARKET RESTRAINTS 38
5.2.2.1 Unclear regulatory guidelines for product development & commercialization 38
5.2.2.2 Socio-ethical issues related to the use of ESCs in disease treatment 39
5.2.3 MARKET GROWTH OPPORTUNITIES 39
5.2.3.1 Supportive regulations across developing countries 39
5.2.3.2 Emergence of iPSCs as an effective alternative to ESCs 40
5.2.4 MARKET CHALLENGES 41
5.2.4.1 Technical limitations related to production scale-up 41
5.3 REGULATORY LANDSCAPE 41
5.3.1 NORTH AMERICA 41
5.3.2 EUROPE 42
5.3.3 ASIA-PACIFIC 44
5.3.4 REST OF THE WORLD 45

6 INDUSTRY INSIGHTS 46
6.1 INTRODUCTION 46
6.2 SUPPLY CHAIN ANALYSIS 46
6.2.1 KEY STAKEHOLDERS 47
6.2.2 KEY INFLUENCERS 47
6.3 PIPELINE ANALYSIS 48
6.3.1 PIPELINE ANALYSIS: BASED ON PHASE OF CLINICAL STUDY 48
6.3.2 PIPELINE ANALYSIS: BASED ON TYPE 49
6.3.3 PIPELINE ANALYSIS: BASED ON THE CELL LINE USED 50

7 GLOBAL STEM CELL THERAPY MARKET, BY TYPE 52
7.1 INTRODUCTION 53
7.2 ALLOGENEIC STEM CELL THERAPY MARKET, BY APPLICATION 54
7.2.1 MUSCULOSKELETAL DISORDERS 55
7.2.2 WOUNDS AND INJURIES 57
7.2.3 SURGERIES 57
7.2.4 ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) 58
7.2.5 OTHER APPLICATIONS 59
7.3 AUTOLOGOUS STEM CELL THERAPY MARKET, BY APPLICATION 59
7.3.1 WOUNDS AND INJURIES 61
7.3.2 CARDIOVASCULAR DISEASES 62
7.3.3 GASTROINTESTINAL DISEASES 63
7.3.4 OTHER APPLICATIONS 64

8 GLOBAL STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION 65
8.1 INTRODUCTION 66
8.2 MUSCULOSKELETAL DISORDERS 67
8.3 WOUNDS AND INJURIES 68
8.4 CARDIOVASCULAR DISEASES 69
8.5 SURGERIES 70
8.6 GASTROINTESTINAL DISEASES 71
8.7 OTHER APPLICATIONS 72

9 GLOBAL STEM CELL THERAPY MARKET, BY CELL SOURCE 73
9.1 INTRODUCTION 74
9.2 ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS 75
9.3 BONE MARROW-DERIVED MESENCHYMAL STEM CELLS 75
9.4 CORD BLOOD/EMBRYONIC STEM CELLS 76
9.5 OTHER CELL SOURCES 77

10 STEM CELL THERAPY MARKET, BY REGION 78
10.1 INTRODUCTION 79
10.2 NORTH AMERICA 79
10.3 EUROPE 83
10.4 ASIA-PACIFIC 86
10.5 REST OF THE WORLD (ROW) 89

11 COMPETITIVE LANDSCAPE 92
11.1 OVERVIEW 92
11.2 MARKET RANKING 92
11.3 STRATEGIC BENCHMARKING 93
11.3.1 PRODUCT DEVELOPMENT AND COMMERCIALIZATION 93
11.4 COMPETITIVE SCENARIO 94
11.5 RECENT DEVELOPMENTS 95
11.5.1 PRODUCT LAUNCHES AND APPROVALS 95
11.5.2 EXPANSIONS 96
11.5.3 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS 97

12 COMPANY PROFILES 98
12.1 INTRODUCTION 98
12.1.1 GEOGRAPHIC BENCHMARKING 98
(Overview, Financials, Products & Services, Strategy, and Developments)*
12.2 OSIRIS THERAPEUTICS, INC. 99
12.3 MEDIPOST CO., LTD. 101
12.4 ANTEROGEN CO., LTD. 104
12.5 PHARMICELL CO., LTD. 105
12.6 HOLOSTEM TERAPIE AVANZATE SRL 107
12.7 JCR PHARMACEUTICALS CO., LTD. 108
12.8 NUVASIVE, INC. 110
12.9 RTI SURGICAL, INC. 111
12.10 ALLOSOURCE 112
*Details on overview, financials, product & services, strategy, and developments might not be captured in case of unlisted companies.

13 APPENDIX 113
13.1 INSIGHTS OF INDUSTRY EXPERTS 113
13.2 DISCUSSION GUIDE 114
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 116
13.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 118
13.5 AVAILABLE CUSTOMIZATIONS 119
13.6 RELATED REPORTS 119
13.7 AUTHOR DETAILS 120

LIST OF TABLES

TABLE 1 FEW OF THE RECENTLY LAUNCHED CELL ANALYSIS PRODUCTS (2015-2017) 37
TABLE 2 NORTH AMERICA: REGULATORY LANDSCAPE FOR STEM CELL THERAPY
(AS OF 2016) 41
TABLE 3 EUROPE: REGULATORY LANDSCAPE FOR STEM CELL THERAPY (AS OF 2016) 42
TABLE 4 ASIA-PACIFIC: REGULATORY LANDSCAPE FOR STEM CELL THERAPY (AS OF 2016) 44
TABLE 5 ROW: REGULATORY LANDSCAPE FOR STEM CELL THERAPY (AS OF 2016) 45
TABLE 6 GLOBAL STEM CELL THERAPY MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION) 53
TABLE 7 GLOBAL ALLOGENEIC STEM CELL THERAPY MARKET SIZE, BY APPLICATION,
2014-2021 (USD MILLION) 54
TABLE 8 GLOBAL ALLOGENEIC STEM CELL THERAPY MARKET SIZE, BY REGION,
2014-2021 (USD MILLION) 55
TABLE 9 ALLOGENEIC STEM CELL THERAPY MARKET SIZE FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2014-2021 (USD MILLION) 56
TABLE 10 ALLOGENEIC STEM CELL THERAPY MARKET SIZE FOR WOUNDS AND INJURIES,
BY REGION, 2014-2021 (USD MILLION) 57
TABLE 11 ALLOGENEIC STEM CELL THERAPY MARKET SIZE FOR SURGERIES, BY REGION, 2014-2021 (USD MILLION) 57
TABLE 12 ALLOGENEIC STEM CELL THERAPY MARKET SIZE FOR ACUTE GRAFT-VERSUS-HOST DISEASE, BY REGION, 2014-2021 (USD MILLION) 58
TABLE 13 ALLOGENEIC STEM CELL THERAPY MARKET SIZE FOR OTHER APPLICATIONS,
BY REGION, 2014-2021 (USD MILLION) 59
TABLE 14 GLOBAL AUTOLOGOUS STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION) 60
TABLE 15 GLOBAL AUTOLOGOUS STEM CELL THERAPY MARKET SIZE, BY REGION,
2014-2021 (USD MILLION) 60
TABLE 16 AUTOLOGOUS STEM CELL THERAPY MARKET FOR WOUNDS AND INJURIES,
BY REGION, 2014-2021 (USD MILLION) 62
TABLE 17 AUTOLOGOUS STEM CELL THERAPY MARKET SIZE FOR CARDIOVASCULAR DISEASES, BY REGION, 2014-2021 (USD MILLION) 63
TABLE 18 AUTOLOGOUS STEM CELL THERAPY MARKET SIZE FOR GASTROINTESTINAL DISEASES, BY REGION, 2014-2021 (USD MILLION) 64
TABLE 19 AUTOLOGOUS STEM CELL THERAPY MARKET SIZE FOR OTHER APPLICATIONS,
BY REGION, 2014-2021 (USD MILLION) 64
TABLE 20 GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2014-2021 (USD MILLION) 66
TABLE 21 STEM CELL THERAPY MARKET SIZE FOR MUSCULOSKELETAL DISORDERS,
BY REGION, 2014-2021 (USD MILLION) 68
TABLE 22 STEM CELL THERAPY MARKET SIZE FOR WOUNDS AND INJURIES, BY REGION, 2014-2021 (USD MILLION) 68
TABLE 23 STEM CELL THERAPY MARKET SIZE FOR CARDIOVASCULAR DISEASES, BY REGION, 2014-2021 (USD MILLION) 69
TABLE 24 STEM CELL THERAPY MARKET SIZE FOR SURGERIES, BY REGION,
2014-2021 (USD MILLION) 70
TABLE 25 STEM CELL THERAPY MARKET SIZE FOR GASTROINTESTINAL DISEASES,
BY REGION, 2014-2021 (USD MILLION) 71
TABLE 26 STEM CELL THERAPY MARKET SIZE FOR OTHER APPLICATIONS, BY REGION,
2014-2021 (USD MILLION) 72
TABLE 27 GLOBAL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE,
2014-2021 (USD MILLION) 74
TABLE 28 STEM CELL THERAPY MARKET SIZE FOR ADIPOSE TISSUE-DERIVED MSCS,
BY REGION, 2014-2021 (USD MILLION) 75
TABLE 29 STEM CELL THERAPY MARKET SIZE FOR BONE MARROW-DERIVED MSCS,
BY REGION, 2014-2021 (USD MILLION) 76
TABLE 30 STEM CELL THERAPY MARKET SIZE FOR CORD BLOOD/EMBRYONIC STEM CELLS, BY REGION, 2014-2021 (USD MILLION) 76
TABLE 31 STEM CELL THERAPY MARKET SIZE FOR OTHER CELL SOURCES, BY REGION, 2014-2021 (USD MILLION) 77
TABLE 32 STEM CELL THERAPY MARKET SIZE, BY REGION, 2014-2021 (USD MILLION) 79
TABLE 33 NORTH AMERICA: STEM CELL THERAPY MARKET SIZE, BY TYPE,
2014-2021 (USD MILLION) 80
TABLE 34 NORTH AMERICA: STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2014-2021 (USD MILLION) 81
TABLE 35 NORTH AMERICA: STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE,
2014-2021 (USD MILLION) 81
TABLE 36 EUROPE: STEM CELL THERAPY MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION) 83
TABLE 37 EUROPE: STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2014-2021 (USD MILLION) 84
TABLE 38 EUROPE: STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE,
2014-2021 (USD MILLION) 84
TABLE 39 ASIA-PACIFIC: STEM CELL THERAPY MARKET SIZE, BY TYPE,
2014-2021 (USD MILLION) 87
TABLE 40 ASIA-PACIFIC: STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2014-2021 (USD MILLION) 87
TABLE 41 ASIA-PACIFIC: STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE,
2014-2021 (USD MILLION) 87
TABLE 42 ROW: STEM CELL THERAPY MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION) 89
TABLE 43 ROW: STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION,
2014-2021 (USD MILLION) 90
TABLE 44 ROW: STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE,
2014-2021 (USD MILLION) 90
TABLE 45 TOP PRODUCT LAUNCHES AND APPROVALS (2013–2016) 95
TABLE 46 TOP EXPANSIONS (2013 – 2016) 96
TABLE 47 TOP AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS (2013-2016) 97
TABLE 48 OSIRIS THERAPEUTICS, INC.: STEM CELL THERAPY PRODUCTS OFFERED 99
TABLE 49 OSIRIS THERAPEUTICS, INC.: STEM CELL THERAPY PRODUCT PIPELINE 99
TABLE 50 MEDIPOST CO., LTD.: STEM CELL THERAPY PRODUCTS OFFERED 102
TABLE 51 MEDIPOST CO., LTD.: STEM CELL THERAPY PRODUCT PIPELINE 102
TABLE 52 ANTEROGEN CO., LTD.: STEM CELL THERAPY PRODUCTS OFFERED 104
TABLE 53 ANTEROGEN CO., LTD.: STEM CELL THERAPY PRODUCT PIPELINE 104
TABLE 54 PHARMICELL CO., LTD.: STEM CELL THERAPY PRODUCTS OFFERED 105
TABLE 55 PHARMICELL CO., LTD.: STEM CELL THERAPY PRODUCT PIPELINE 105
TABLE 56 HOLOSTEM TERAPIE AVANZATE SRL: STEM CELL THERAPY PRODUCTS OFFERED 107

TABLE 57 JCR PHARMACEUTICALS CO., LTD.: STEM CELL THERAPY PRODUCTS OFFERED 109
TABLE 58 NUVASIVE, INC.: STEM CELL THERAPY PRODUCTS OFFERED 110
TABLE 59 RTI SURGICAL, INC.: STEM CELL THERAPY PRODUCTS OFFERED 111
TABLE 60 ALLOSOURCE: STEM CELL THERAPY PRODUCTS OFFERED 112


LIST OF FIGURES

FIGURE 1 RESEARCH DESIGN 19
FIGURE 2 BOTTOM-UP APPROACH 22
FIGURE 3 TOP-DOWN APPROACH 23
FIGURE 4 DATA TRIANGULATION 24
FIGURE 5 ASSUMPTIONS FOR THE STUDY 25
FIGURE 6 ALLOGENEIC STEM CELL THERAPY DOMINATES THE STEM CELL THERAPY MARKET IN 2016 27
FIGURE 7 MUSCULOSKELETAL DISORDERS COMMANDS THE LARGEST SHARE OF THE STEM CELL THERAPY MARKET IN 2016 27
FIGURE 8 ADIPOSE TISSUE-DERIVED MSCS WILL CONTINUE TO DOMINATE THE STEM CELL THERAPY MARKET TILL 2021 28
FIGURE 9 STEM CELL THERAPY MARKET SHARE, BY REGION 29
FIGURE 10 EMERGING COUNTRIES OFFER HIGH-GROWTH OPPORTUNITIES TO PLAYERS IN THE STEM CELL THERAPY MARKET 30
FIGURE 11 ALLOGENEIC STEM CELL THERAPY TO DOMINATE THE GLOBAL STEM CELL THERAPY MARKET DURING FORECAST PERIOD 31
FIGURE 12 MUSCULOSKELATAL DISORDERS SEGMENT TO DOMINATE THE GLOBAL STEM CELL THERAPY MARKET DURING FORECAST PERIOD 32
FIGURE 13 ADIPOSE TISSUE-DERIVED CELL SOURCE SEGMENT TO DOMINATE THE STEM CELL THERAPY MARKET DURING FORECAST PERIOD 33
FIGURE 14 GROWING PUBLIC AWARENESS RELATED TO THERAPEUTIC POTENCY OF STEM CELLS IS AUGMENTING THE MARKET GROWTH DURING THE STUDY PERIOD 35
FIGURE 15 MARKET PLAYERS PREFER BOTH DIRECT & INDIRECT DISTRIBUTION STRATEGIES FOR STEM CELL THERAPY PRODUCTS ACROSS MAJOR GEOGRAPHIES 46
FIGURE 16 MAJORITY OF STEM CELL THERAPY CANDIDATE PRODUCTS ARE IN PRECLINICAL PHASE, FOLLOWED BY PHASE 1 & PHASE 1/2 48
FIGURE 17 ALLOGENEIC STEM CELL THERAPY PIPELINE PRODUCTS ACCOUNT FOR A LARGER SHARE OF THE OVERALL STEM CELL THERAPY PRODUCTS UNDER DEVELOPMENT 49
FIGURE 18 ALLOGENEIC STEM CELL THERAPY PIPELINE PRODUCTS: BASED ON STUDY PHASES 49
FIGURE 19 AUTOLOGOUS STEM CELL THERAPY PIPELINE PRODUCTS: BASED ON STUDY PHASES 50
FIGURE 20 BONE MARROW-DERIVED MESENCHYMAL STEM CELLS ARE PREFERRED
FOR STEM CELL THERAPY DEVELOPMENT 50
FIGURE 21 ALLOGENEIC STEM CELL THERAPY TO DOMINATE THE GLOBAL STEM CELL THERAPY MARKET TILL 2021 53
FIGURE 22 MUSCULOSKELATAL DISORDERS TO DOMINATE THE ALLOGENEIC STEM CELL THERAPY MARKET TILL 2021 55
FIGURE 23 WOUNDS AND INJURIES MARKET TO DOMINATE THE AUTOLOGOUS STEM CELL THERAPY MARKET TILL 2021 61
FIGURE 24 MUSCULOSKELATAL DISORDERS SEGMENT TO DOMINATE GLOBAL STEM CELL THERAPY MARKET TILL 2021 67
FIGURE 25 ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS TO DOMINATE THE GLOBAL STEM CELL THERAPY MARKET TILL 2021 74
FIGURE 26 NORTH AMERICA: STEM CELL THERAPY MARKET SNAPSHOT 82
FIGURE 27 EUROPE: STEM CELL THERAPY MARKET SNAPSHOT 85
FIGURE 28 ASIA PACIFIC: STEM CELL THERAPY MARKET SNAPSHOT 88
FIGURE 29 ROW: STEM CELL THERAPY MARKET SNAPSHOT 91
FIGURE 30 GLOBAL STEM CELL THERAPY MARKET RANKING (2015) 92
FIGURE 31 PRODUCT DEVELOPMENT AND COMMERCIALIZATION: THE KEY GROWTH STRATEGY ADOPTED BY STEM CELL THERAPY MARKET PLAYERS (2013-2016) 93
FIGURE 32 PRODUCT LAUNCHES AND ENHANCEMENTS: KEY STRATEGY ADOPTED
BY MAJORITY OF KEY PLAYERS DURING STUDY PERIOD 94
FIGURE 33 GEOGRAPHIC REVENUE MIX OF THE TOP FIVE PLAYERS (2015) 98
FIGURE 34 MEDIPOST CO., LTD.: COMPANY SNAPSHOT (2015) 101
FIGURE 35 JCR PHARMACEUTICALS CO., LTD.: COMPANY SNAPSHOT (2015) 108
FIGURE 36 NUVASIVE, INC.: COMPANY SNAPSHOT (2015) 110
FIGURE 37 RTI SURGICAL, INC.: COMPANY SNAPSHOT (2015) 111


【レポートのキーワード】

幹細胞治療、同種幹細胞、同種造血幹細胞移植、自己幹細胞、医療

★調査レポート[幹細胞治療の世界市場予測(~2021年):同種幹細胞、自己幹細胞] ( Stem Cell Therapy Market by Type (Allogeneic, Autologous), Therapeutic Application (Musculoskeletal, Wound & Injury, CVD, Surgery, and aGVHD), Cell Source (Adipose tissue, Bone Marrow, Neural, Embryo/Cord Blood derived, iPSCs) - Global Forecasts to 2021 / MAM-BT5049) 販売に関する免責事項
[幹細胞治療の世界市場予測(~2021年):同種幹細胞、自己幹細胞] ( Stem Cell Therapy Market by Type (Allogeneic, Autologous), Therapeutic Application (Musculoskeletal, Wound & Injury, CVD, Surgery, and aGVHD), Cell Source (Adipose tissue, Bone Marrow, Neural, Embryo/Cord Blood derived, iPSCs) - Global Forecasts to 2021 / MAM-BT5049) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆